Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Accropeutics to Start Phase I Trial of TYK2/JAK1 Inhibitor for Psoriasis

publication date: May 25, 2023

Suzhou Accropeutics Bioscience was approved to start a Phase I trial of its oral small molecule TYK2/JAK1 inhibitor in Australia. The company says AC-201 has shown efficacy in multiple animal disease models including psoriasis with the possibility of treating other inflammatory and autoimmune diseases. The trial will be a randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of AC-201 in healthy adults. Accropeutics focuses on molecular mechanisms of regulated cell death and related pathogenesis in human diseases. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital